We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Pfizer CDR CAD Hedged | NEO:PFE | NEO | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.06 | -0.49% | 12.22 | 12.04 | 12.07 | 12.22 | 12.22 | 12.22 | 14,965 | 14:53:29 |
From Mar 2023 to Mar 2025
By Colin Kellaher
Pfizer and Genmab on Tuesday said the U.S. Food and Drug Administration granted priority review to their request to convert the accelerated approval of Tivdak for certain patients with cervical cancer to full approval.
The companies said the FDA has set a target action date of May 9 for the application, which is based on positive results from a global Phase 3 study that showed overall survival benefit of Tivdak over chemotherapy in patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.
The FDA granted accelerated approval to Tivdak in September 2021.
Copenhagen biotechnology company Genmab and Seagen, which New York-based Pfizer acquired last year in a $43 billion deal, are co-developing Tivdak by Genmab and Seagen, under an agreement in which the companies share costs and profits for the product on a 50-50 basis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 09, 2024 07:30 ET (12:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Pfizer CDR CAD Hedged Chart |
1 Month Pfizer CDR CAD Hedged Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
